Skip to main content
Article thumbnail
Location of Repository

doi:10.1017/S0033291707001924 Printed in the United Kingdom Vagus nerve stimulation for depression: efficacy and safety in a European study ORIGINAL ARTICLE

By T. E. Schlaepfer, C. Frick, A. Zobel, W. Maier, I. Heuser, M. Bajbouj, C. Corcoran, R. Adolfsson, M. Trimble, H. Rau, H. -j. Hoff, F. Padberg and F. Müller-siecheneder


Background. Vagus nerve stimulation (VNS) therapy is associated with a decrease in seizure frequency in partial-onset seizure patients. Initial trials suggest that it may be an effective treatment, with few side-effects, for intractable depression. Method. An open, uncontrolled European multi-centre study (D03) of VNS therapy was conducted, in addition to stable pharmacotherapy, in 74 patients with treatment-resistant depression (TRD). Treatment remained unchanged for the first 3 months; in the subsequent 9 months, medications and VNS dosing parameters were altered as indicated clinically. Results. The baseline 28-item Hamilton Depression Rating Scale (HAMD-28) score averaged 34. After 3 months of VNS, response rates (o50 % reduction in baseline scores) reached 37 % and remission rates (HAMD-28 score <10) 17%. Response rates increased to 53 % after 1 year of VNS, and remission rates reached 33%. Response was defined a

Year: 2010
OAI identifier: oai:CiteSeerX.psu:
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.